Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06263660

Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression

Exploratory Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of a Keto-Like Supplement in Depressed Patients on Functional Brain Responses to Positive and Negative Stimuli

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
75 (estimated)
Sponsor
Laureate Institute for Brain Research, Inc. · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study aims to determine whether a keto-like supplement relative to placebo results in functional brain changes during fMRI tasks evaluating positive and negative valence in individuals with moderate to severe depression. In this double-blind randomized placebo-controlled trial, 75 individuals with a Patient Health Questionnaire (PHQ-9) scale score ≥ 10 (MDD) will be enrolled to participate in an 8-week treatment study to obtain 60 completers. Participants will be randomized with a 1-1 ratio to receive the keto-like supplement (n= 30 completers) or placebo (n=30 completers) taken orally three times per day for 8 weeks. Participants will undergo a 10.5-hour screening/baseline evaluation visit split over 2 days at week 0 including questionnaires, neuroimaging before and after supplement or placebo administration and blood draws, office visits at week 2 (1.5 hours), week 4 (3 hours), week 6 (0.5 hours), week 8 (6 hours), a follow-up visit at week 10 (1.5 hours) and two phone calls between visits (weeks 1 and 3) during which a brief clinical assessment will be obtained (10 minutes each). The total time involved in the study is approximately 23.5 hours.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTKeto-like supplementParticipants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.
DIETARY_SUPPLEMENTPlaceboParticipants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.

Timeline

Start date
2024-01-09
Primary completion
2026-12-31
Completion
2027-12-01
First posted
2024-02-16
Last updated
2026-04-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06263660. Inclusion in this directory is not an endorsement.